Literature DB >> 26361097

Impact of Disease Duration on Vascular Surrogates of Early Atherosclerosis in Childhood-Onset Systemic Lupus Erythematosus.

Julie Barsalou1, Timothy J Bradley1, Pascal N Tyrrell2, Cameron Slorach1, Lawrence W K Ng1, Deborah M Levy1, Earl D Silverman3.   

Abstract

OBJECTIVE: To determine whether longer disease duration negatively impacts carotid intima-media thickness (CIMT), flow-mediated dilation (FMD), and pulse wave velocity (PWV) in a cohort of patients with childhood-onset systemic lupus erythematosus (SLE), and to compare CIMT, FMD, and PWV in patients with childhood-onset SLE with those in healthy children and explore determinants of vascular test results in childhood-onset SLE.
METHODS: Cross-sectional analysis was performed in a prospective longitudinal cohort of patients with childhood-onset SLE at the latest followup visit. Clinical and laboratory data were collected for patients with childhood-onset SLE. CIMT, FMD, and PWV were measured using standardized protocols in patients with childhood-onset SLE and healthy children. Correlations between disease duration and results of the 3 vascular tests were performed. Vascular data in patients with childhood-onset SLE were compared with those in healthy children. Multivariable linear regression was used to identify determinants of CIMT, FMD, and PWV in childhood-onset SLE.
RESULTS: Patients with childhood-onset SLE (n = 149) and healthy controls (n = 178) were enrolled. The median age of the patients was 17.2 years (interquartile range [IQR] 15.7-17.9 years), and their median disease duration was 3.2 years (IQR 1.8-4.9 years). The median age of the healthy children was 14.7 years (IQR 13.1-15.9 years). Longer disease duration correlated with worse FMD (r = -0.2, P = 0.031) in patients with childhood-onset SLE. Patients with childhood-onset SLE had smaller (better) CIMT, higher (better) FMD, and similar PWV compared with healthy controls. Linear regression analysis explained <24% of the variation in vascular test results in patients with childhood-onset SLE, suggesting that other variables should be explored as important determinants of CIMT, FMD, and PWV.
CONCLUSION: In this cohort of 149 patients with childhood-onset SLE, patients did not have worse CIMT, FMD, or PWV than did healthy controls. Longer disease duration was associated with worse FMD, suggesting progressive endothelial dysfunction over time.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26361097     DOI: 10.1002/art.39423

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  5 in total

1.  Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients.

Authors:  Mai A Abd-Elmawla; Mary Wadie Fawzy; Sherine M Rizk; Amira A Shaheen
Journal:  Clin Rheumatol       Date:  2018-08-21       Impact factor: 2.980

Review 2.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

Review 3.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

4.  Endothelial dysfunction in systemic lupus erythematosus - a case-control study and an updated meta-analysis and meta-regression.

Authors:  Anselm Mak; Nien Yee Kow; Herbert Schwarz; Lingli Gong; Sen Hee Tay; Lieng Hsi Ling
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

5.  Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus.

Authors:  Priscila B S Medeiros; Roberta G Salomão; Sara R Teixeira; Diane M Rassi; Luciana Rodrigues; Davi C Aragon; Priscila G Fassini; Fábio V Ued; Rita C Tostes; Jacqueline P Monteiro; Virgínia P L Ferriani; Luciana M de Carvalho
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-20       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.